PTK2B
Protein-tyrosine kinase 2-beta
As of the edition of 20 October 2026, PTK2B (protein-tyrosine kinase 2-beta, UniProt Q14289) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q14289
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 26
- Disease areas
- Cancer; Hormones; Digestive system; Lungs and airways; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Heart and blood vessels
- Registered trials of its drugs
- 41
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Status not established | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Defactinib | Marketed | Phase 3 | none listed |
| Conteltinib | Status not established | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 2 |